Trials / Unknown
UnknownNCT04730648
Acute Myocardial Infarction and Unstable Angina Patients With PCSK9 Inhibitor Usage Study
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Shenzhen People's Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Acute coronary syndrome (ACS) is a lethal disease, reduced low-density lipoprotein (LDL) cholesterol due to inhibition of proprotein convertase subtilisin/kexin 9 (PCSK9) reduces cardiovascular events and improve cardiovascular prognosis. we assuming that PCSK9 inhibitor could bring metabolic change in serum, in order to investigate the metabolic modification, we conduct this clinical trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PCSK9 inhibitor | For newly diagnosed ACS patients with diabetes, multivessel occlusion, or recurrent ACS attack, who are willing to accept PCSK9 inhibitor injection. |
Timeline
- Start date
- 2021-04-22
- Primary completion
- 2022-04-23
- Completion
- 2023-04-23
- First posted
- 2021-01-29
- Last updated
- 2022-05-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04730648. Inclusion in this directory is not an endorsement.